AliveCor Archives - Medical Design Sourcing

Court grants AliveCor stay in patent battle with Apple as PTAB investigation goes on

A figure from AliveCor’s patent, included in the PTAB ruling

The United States District Court of the Northern District of California allowed AliveCor a stay in legal proceedings against tech giant Apple.

AliveCor and Apple have a longstanding legal battle ongoing over the use of ECG technology for detecting AFib. Last week, the U.S. Patent Trial and Appeal Board’s (PTAB) agreed to institute three of AliveCor’s Inter Partes Reviews (IPR) against Apple’s countersuit. The PTAB previously ruled in December 2022 that AliveCor’s claims surrounding U.S. Patent No. 10,595,731 B2 were unpatentable. This proved a setback to AliveCor in the intellectual property fight with Apple and its AFib detection technology.

The latest ruling confirms a continuation of the stay requested by AliveCor until all IPRs in the case are heard. AliveCor views Apple’s countersuit as an effort to derail its original patent infringement case over the ECG technology.

…

PTAB to review Apple’s ECG patents amid legal battle with AliveCor

A figure from AliveCor’s patent, included in the PTAB ruling

The U.S. Patent Trial and Appeal Board (PTAB) will review two Apple-owned electrocardiogram technology patents in an infringement suit as AliveCor looks to reverse the board’s opinion from December 2023.

A panel of administrative patent judges granted AliveCor’s bid for a review, citing a “reasonable likelihood” that AliveCor would successfully show the unpatentability of Apple’s technology. The PTAB will formally review the validity of certain patent claims, considering AliveCor’s arguments. However, it’s important to note that this is just the beginning of the process, and no final decisions on the patentability of the claims have been made yet.

In a statement to MassDevice, AliveCor said: “AliveCor applauds the U.S. Patent Trial and Appeal Board (PTAB) decisions to institute Inter Partes Review (IPR) of two patents Apple meritlessly asserted aga…

AliveCor, Luscii partner on ‘heart clinic in a box’

AliveCor announced today that it entered into a collaboration with Luscii to launch a “virtual heart clinic in a box.”

The companies aim to revolutionize cardiac care by enabling the delivery of high-quality remote patient monitoring. Luscii, a Europe-based remote patient monitoring and virtual ward provider, develops its Virtual Heart Clinic. The company aims to provide cardiologists with a comprehensive, easy-to-use remote cardiac monitoring app.

Luscii’s Virtual Heart Clinic prompts patients to take measures of vital signs that are automatically analyzed to detect abnormalities. This results in an improved patient experience and more time to care for the clinical teams.

About the collaboration between AliveCor and Luscii

Through the collaboration, Luscii plans to integrate the AliveCor six-lead ECG technology next to Omron blood pressure meters.

“We are excited to partner with Luscii utilizing AliveCor’s SDK soluti…

The biggest medical device VC deals of 2022

Enable Injections, which makes the enFuse device, raised $215 million in January 2022. [Photo courtesy of Enable Injections]

Last year was definitely a slower year for medical device VC deals than the year before.

Biofourmis was the only medical device developer in the 10 largest healthcare VC deals of 2022, according to a ranking provided to Medical Design & Outsourcing by Silicon Valley Bank (SVB).

Because we love devices at Medical Design & Outsourcing, we asked SVB for a ranking of 2022’s largest medical device VC deals after Biofourmis, which raised $325 million in its 2022 series D round. (The year before that, CMR Surgical’s $600 million Series D financing round was the largest medical device VC deal of 2021.)

SVB obliged, once again drawing upon its own proprietary information and data from Pitchbook. The dealmakers include device developers with innovative methods for …

President Biden upholds ITC ruling favoring AliveCor in Apple patent spat

A figure from AliveCor’s patent, included in the PTAB ruling

AliveCor announced today that the final determination ruled on its patent dispute with Apple cleared presidential review.

In December, the International Trade Commission (ITC) ruled that the Apple Watch infringed AliveCor’s patented technology.

Along with its final determination, the ITC issued a limited exclusion disorder (LEO) and a cease and desist order. It set a bond in the amount of $2 per unit of infringing Apple Watches imported or sold during its review period. The LEO goes into effect upon the favorable resolution of appeals in the case. That includes AliveCor’s appeal of a U.S. Patent Trial and Appeal Board decision.

Mountain View, California-based AliveCor said in a news release that it marks the ITC’s first LEO against Apple to clear presidential review. The company believes it “sends a strong signal” to companies that AliveCor’s IP is prot…

At-home predictive care and the shifting patient experience

The eMed platform connects patients with telehealth providers for home testing. [Photo courtesy of eMed]

These medtech developers are advancing remote patient monitoring, virtual care, and AI predictive care.

Robin Farmanfarmaian

The combination of remote patient monitoring (RPM), virtual care and AI predictive care is changing the patient experience. Instead of the occasional clinic visit, people can interact with their healthcare daily and on-demand.

Here are a few of the medtech startups advancing remote, continuous and predictive care. Together, these companies enable truly personalized care, tailored to someone in their daily life and environment.

Remote patient monitoring (RPM)

There are many technology devices that have cleared the FDA and qualify as remote physiologic monitoring under the Medicare CPT codes. Medicare also has remote therapeutic monitoring CPT codes for musculoskeletal …

ITC rules in favor of AliveCor in patent spat with Apple

A figure from AliveCor’s patent, included in the PTAB ruling

AliveCor announced today that the International Trade Commission (ITC) ruled that the Apple Watch infringed its patented technology.

Along with the final determination, the ITC issued a limited exclusion disorder (LEO) and a cease and desist order. It set a bond in the amount of $2 per unit of infringing Apple Watches imported or sold during its review period.

In a news release, AliveCor said it could potentially impact sales of “millions of infringing Apple Watches.”

“Today’s ITC ruling is a win for innovation and consumer choice,” said Priya Abani, CEO of AliveCor. “The ruling underscores the importance of upholding intellectual property rights for companies like AliveCor and scores of others whose innovations are at risk of being suppressed by a Goliath like Apple. We look forward to continuing to build and innovate on our cardiac solutions to improve people’s l…

Apple scores a win in IP spat with AliveCor

A figure from AliveCor’s patent from in the PTAB ruling

The U.S. Patent Trial and Appeal Board has dealt AliveCor a setback in its intellectual property fight with Apple over the technology behind wearable AFib detection.

In a ruling entered yesterday, the PTAB agreed with Apple that AliveCor’s claims around U.S. Patent No. 10,595,731 B2 were unpatentable. The board made the determination based on the IP law concept of obviousness. Basically, someone with ordinary skills in the field would have found the patent obvious. They could have created what AliveCor was patenting based on the research and technological advancements that had already taken place.

The PTAB said: “Considering all the art and argument of record, and the level of ordinary skill in the art, we agree with [Apple] that ‘after an ECG is measured, it would have been obvious to confirm arrhythmia detection using a machine learning algorithm based on the PPG data, motion sens…

GE Healthcare leads AliveCor Series F funding for ECG tech

AliveCor today announced a Series F financing led by GE Healthcare.

The FDA-cleared personal electrocardiogram tech company did not disclose the size of the funding round. NGK-NTK, through a CVC partnership with Pegasus Tech Ventures, also joined the round. The round also included existing investors Khosla Ventures, Bold Capital Partners, Qualcomm Ventures and WP Global Partners.

The infusion of funds from GE comes five months after GE Healthcare and AliveCor announced a partnership. People with an AliveCor KardiaMobile 6L ECG device outside of the hospital can have their data go directly to GE Healthcare’s Muse cardiac management system. Physicians can then view and evaluate the information. The is to hopefully spot atrial fibrillation and other cardiac conditions before they send someone to the hospital.

“GE Healthcare is committed to providing advanced technologies that better connect data and create actionable insights for clinicians to serve p…

AliveCor launches KardiaComplete heart health management platform

AliveCor announced today that it launched its KardiaComplete comprehensive heart health enterprise solution.

Mountain View, California-based AliveCor designed the KardiaComplete platform to drive improved health outcomes and reduce the cost of cardiac care for people diagnosed with hypertension and arrhythmias, like AFib, through their self-insured employers, health insurance plans and health systems.

The company said in a news release that KardiaComplete leverages data from its KardiaMobile 6L electrocardiogram (ECG), as well as Omron’s Evolv blood pressure cuff, to meet needs for coaching and care in moments that matter. The platform’s live and digital heart health coaching helps to address heart conditions with lifestyle management tools promoting heart-healthy diet, movement, stress management and healthy sleep.

Additionally, the KardiaComplete platform offers support from a virtual assistant and personalized analyses of heart data to emp…

GE Healthcare, AliveCor partner to reduce cardiac-related hospitalizations

GE Healthcare’s MUSE platform (left) and AliveCor’s KardiaMobile 6L (right). [Images from GE Healthcare and AliveCor]GE Healthcare (NYSE:GE) and AliveCor announced today that they partnered to deliver electrocardiograms (ECGs) outside the hospital.

AliveCor develops the KardiaMobile 6L (six-lead) ECG to detect AFib and other heart rhythm conditions. The partnership aims to deliver KardiaMobile’s six-lead ECGs taken by patients directly into GE Healthcare’s MUSE cardiac management system for physicians to view and evaluate.

According to a news release, the companies believe integrating the technologies will offer physicians access to trusted patient data within their existing workflow, increasing diagnostic confidence and enhancing the management of patients across the care continuum. GE Healthcare and AliveCor partnered with a goal of reducing hospitalizations linked to cardiac conditions, including but not limited to AFib.

GE Health…

FDA clears AliveCor’s next-generation credit card-sized ECG device

[Image from AliveCor]AliveCor announced today that it received FDA clearance for and launched its next-generation KardiaMobile electrocardiogram (ECG) device.

Mountain View, California-based AliveCor touts the KardiaMobile Card as the slimmest, most convenient personal ECG device ever made, designed at the size of a standard credit card, fitting into wallets and providing a medical-grade, single-lead ECG in 30 seconds.

According to a news release, AliveCor’s KardiaMobile Card represents the first credit-card-sized ECG to garner FDA clearance.

“After disrupting traditional ECG monitoring with our game-changing Kardia platform, we have now achieved the unprecedented milestone of creating the first-ever credit-card-sized personal ECG,” AliveCor CEO Priya Abani said in the release. “KardiaMobile Card delivers the most sophisticated AI in the most convenient form factor ever, putting the power of real-time ECG analysis directly in patient…